Compare ONMD & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ONMD | ELOX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1M | 60.3M |
| IPO Year | 2021 | 2013 |
| Metric | ONMD | ELOX |
|---|---|---|
| Price | $0.70 | $17.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 165.4K | 33.9K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,359,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 111.35 | N/A |
| 52 Week Low | $0.49 | $10.00 |
| 52 Week High | $4.22 | $23.40 |
| Indicator | ONMD | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 56.03 |
| Support Level | $0.58 | $16.50 |
| Resistance Level | $0.70 | $19.66 |
| Average True Range (ATR) | 0.04 | 2.10 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 57.87 | 83.10 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.